A review on the risk of myocardial infarction associated with the NSAID diclofenac

Cardiovascular and Hematological Disorders - Drug Targets

Volumn 10, Issue 1, 2010, Pages 53-65

  Krötz, Florian ^a   Struthmann, Lena ^b  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY OF KIEL   (Germany)

Author keywords

Cyclooxygenase; Diclofenac; Myocardial infarction; NSAID

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; DICLOFENAC; ETORICOXIB; IBUPROFEN; INDOMETACIN; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PLACEBO; ROFECOXIB; VALDECOXIB;

ARTERY THROMBOSIS; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CLINICAL TRIAL; DRUG MECHANISM; DRUG WITHDRAWAL; GASTROINTESTINAL SYMPTOM; HEART INFARCTION; HUMAN; ISCHEMIC HEART DISEASE; OSTEOARTHRITIS; REVIEW; RHEUMATOID ARTHRITIS; STROKE; SYSTEMATIC REVIEW;

EID: 77950630920     PISSN: 1871529X     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152910790780041     Document Type: Review

References (62)

1. Bombardier, C.; Laine, L.; Reicin, A.; Shapiro, D.; Burgos-Vargas, R.; Davis, B.; Day, R.; Ferraz, M.B.; Hawkey, C.J.; Hochberg, M.C.; Kvien, T.K.; Schnitzer, T.J.; VIGOR Study Group. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N. Engl. J. Med., 2000, 343, 1520-8, 2 p following 8.
2. FitzGerald G.A. COX-2 and beyond: Approaches to prostaglandin inhibition in human disease. Nat. Rev. Drug. Discov., 2003, 2, 879-890.
3. Krotz, F.; Schiele, T.M.; Klauss, V.; Sohn, H.Y. Selective COX-2 inhibitors and risk of myocardial infarction. J. Vasc. Res., 2005, 42, 312-324.
4. Bresalier, R.S.; Sandler, R.S.; Quan, H.; et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N. Engl. J. Med., 2005, 352, 1092-1102.
5. Baron, J.A.; Sandler, R.S.; Bresalier, R.S.; Bolognese, J.A.; Oxenius, B.; Horgan, K.; Lines, C.; Riddell, R.; Morton, D.; Lanas, A.; Konstam, M.A.; Baron, J.A. Cardiovascular events associated with rofecoxib: final analysis of the APPROVe trial. Lancet, 2008, 372, 1756-1764.
6. Capone, M.L.; Tacconelli, S.; Di Francesco, L.; Sacchetti, A.; Sciulli, M.G.; Patrignani, P. Pharmacodynamic of cyclooxygenase inhibitors in humans. Prostaglandins Other Lipid Mediat., 2007, 82, 85-94.
7. Warner, T.D.; Mitchell, J.A. Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic. FASEB J., 2004, 18, 790-804.
8. Serhan, C.N.; Oliw, E. Unorthodox routes to prostanoid formation: new twists in cyclooxygenase-initiated pathways. J. Clin. Invest., 2001, 107, 1481-1489.
9. Okahara, K.; Sun, B.; Kambayashi, J. Upregulation of prostacyclin synthesis-related gene expression by shear stress in vascular endothelial cells. Arterioscler. Thromb. Vasc. Biol., 1998, 18, 1922-1926.
10. Bryant, C.E.; Appleton, I.; Mitchell, J.A. Vascular endothelial growth factor upregulates constitutive cyclooxygenase 1 in primary bovine and human endothelial cells. Life Sci., 1998; 62, 2195-2201.
11. Tanabe, T.; Tohnai, N. Cyclooxygenase isozymes and their gene structures and expression. Prostaglandins Other Lipid Mediat, 2002, 68-69, 95-114.
12. Schildknecht, S.; Bachschmid, M.; Baumann, A.; Ullrich, V. COX- 2 inhibitors selectively block prostacyclin synthesis in endotoxin-exposed vascular smooth muscle cells. FASEB J., 2004, 18, 757-759.
13. Kis, B.; Snipes, J.A.; Busija, D.W. Acetaminophen and the cyclooxygenase-3 puzzle: sorting out facts, fictions, and uncertainties. J. Pharmacol. Exp. Ther., 2005, 315, 1-7.
14. Nakahata, N. Thromboxane A2: physiology/pathophysiology, cellular signal transduction and pharmacology. Pharmacol. Ther., 2008, 118, 18-35.
15. Miyata, A.; Hara, S.; Yokoyama, C.; Inoue, H.; Ullrich, V.; Tanabe, T. Molecular cloning and expression of human prostacyclin synthase. Biochem. Biophys. Res. Commun., 1994, 200, 1728-1734.
16. Wu, K.K.; Liou, J.Y. Cellular and molecular biology of prostacyclin synthase. Biochem. Biophys. Res. Commun., 2005, 338, 45-52.
17. Bauersachs, J.; Popp, R.; Hecker, M.; Sauer, E.; Fleming, I.; Busse, R. Nitric oxide attenuates the release of endothelium-derived hyperpolarizing factor. Circulation, 1996, 94, 3341-3347.
18. Krotz, F.; Hellwig, N.; Burkle, M.A.; Lehrer, S.; Riexinger, T.; Mannell H.; Sohn H.-Y.; Klauss, V.; Pohl U. A sulfaphenazole-sensitive EDHF opposes platelet endothelium interactions in vitro and in the hamster microcirculation in vivo. Cardiovasc. Res., 2010, 85(3), 542-550.
19. Van Der Ouderaa, F.J.; Buytenhek, M.; Nugteren, D.H.; Van Dorp, D.A. Acetylation of prostaglandin endoperoxide synthetase with acetylsalicylic acid. Eur. J. Biochem., 1980, 109, 1-8.
20. Willis, J.V.; Kendall, M.J.; Flinn, R.M.; Thornhill, D.P.; Welling, P.G. The pharmacokinetics of diclofenac sodium following intravenous and oral administration. Eur. J. Clin. Pharmacol., 1979, 16, 405-410.
21. FDA. Available at: http://www.accessdata.fda.gov/drugsatfda- docs/label/2009/020254s018.pdf
22. Patrono, C.; Patrignani, P.; Garcia, Rodriguez L.A. Cyclooxygenase- selective inhibition of prostanoid formation: transducing biochemical selectivity into clinical read-outs. J. Clin. Invest., 2001, 108, 7-13.
23. Hinz, B.; Dormann, H.; Brune, K. More pronounced inhibition of cyclooxygenase 2, increase in blood pressure, and reduction of heart rate by treatment with diclofenac compared with celecoxib and rofecoxib. Arthritis. Rheum., 2006, 54, 282-291.
24. Silverstein, F.E.; Faich, G.; Goldstein, J.L.; Simon, L.S.; Pincus, T.; Whelton, A.; Makuch, R.; Eisen, G.; Agrawal, N.M.; Stenson, W.F.; Burr, A.M.; Zhao, W.W.; Kent, J.D.; Lefkowith, J.B.; Verburg, K.M.; Geis, G.S. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA, 2000, 284, 1247-1255.
25. Singh, G.; Wu, O.; Langhorne, P.; Madhok, R. Risk of acute myocardial infarction with nonselective non-steroidal anti-inflammatory drugs: a meta-analysis. Arthritis Res. Ther., 2006, 8, R153.
26. Hippisley-Cox, J.; Coupland, C. Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional nonsteroidal anti-inflammatory drugs: population based nested casecontrol analysis. BMJ, 2005, 330, 1366.
27. Fischer, L.M.; Schlienger, R.G.; Matter, C.M.; Jick, H.; Meier, C.R. Current use of nonsteroidal antiinflammatory drugs and the risk of acute myocardial infarction. Pharmacotherapy, 2005, 25, 503-510.
28. Garcia Rodriguez, L.A.; Gonzalez-Perez, A. Long-term use of non-steroidal anti-inflammatory drugs and the risk of myocardial infarction in the general population. BMC Med., 2005, 3, 17.
29. Garcia Rodriguez, L.A.; Varas-Lorenzo, C.; Maguire, A.; Gonzalez-Perez, A. Nonsteroidal antiinflammatory drugs and the risk of myocardial infarction in the general population. Circulation, 2004, 109, 3000-3006.
30. Schlienger, R.G.; Jick, H.; Meier, C.R. Use of nonsteroidal anti-inflammatory drugs and the risk of first-time acute myocardial infarction. Br. J. Clin. Pharmacol., 2002, 54, 327-332.
31. McGettigan, P.; Henry, D. Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA, 2006, 296, 1633-1644.
32. Kearney, P.M.; Baigent, C.; Godwin, J.; Halls, H.; Emberson, J.R.; Patrono, C. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ, 2006, 332, 1302-1308.
33. Andersohn, F.; Suissa, S.; Garbe, E. Use of first- and second-generation cyclooxygenase-2-selective nonsteroidal anti-inflammatory drugs and risk of acute myocardial infarction. Circulation, 2006, 113, 1950-1957.
34. Solomon, D.H.; Avorn, J.; Sturmer, T.; Glynn, R.J.; Mogun, H.; Schneeweiss, S. Cardiovascular outcomes in new users of coxibs and nonsteroidal antiinflammatory drugs: high-risk subgroups and time course of risk. Arthritis Rheum., 2006, 54, 1378-1389.
35. Gislason, G.H.; Jacobsen, S.; Rasmussen, J.N.; Rasmussen, S.; Buch, P.; Friberg, J.; Schramm, T.K.; Abildstrom, S.Z.; Køber, L.; Madsen, M.; Torp-Pedersen, C. Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs after acute myocardial infarction. Circulation, 2006, 113, 2906-2913
36. Schneeweiss, S.; Solomon, D.H.; Wang, P.S.; Rassen, J.; Brookhart, M.A. Simultaneous assessment of short-term gastrointestinal benefits and cardiovascular risks of selective cyclooxygenase 2 inhibitors and nonselective nonsteroidal antiinflammatory drugs: an instrumental variable analysis. Arthritis Rheum., 2006, 54, 3390-3398.
37. Rahme, E.; Watson, D.J.; Kong, S.X.; Toubouti, Y.; LeLorier, J. Association between nonnaproxen NSAIDs, COX-2 inhibitors and hospitalization for acute myocardial infarction among the elderly: a retrospective cohort study. Pharmacoepidemiol. Drug Saf., 2007, 16, 493-503.
38. Rahme, E.; Nedjar, H. Risks and benefits of COX-2 inhibitors vs non-selective NSAIDs: does their cardiovascular risk exceed their gastrointestinal benefit? A retrospective cohort study. Rheumatology (Oxford), 2007, 46, 435-438.
39. Chen, Y.F.; Jobanputra, P.; Barton, P.; Bryan, S.; Fry-Smith, A.; Harris, G.; Taylor, R.S. Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation. Health Technol. Assess., 2008, 12, 1-278, iii.
40. Jick, S.S.; Kaye, J.A.; Jick, H. Diclofenac and acute myocardial infarction in patients with no major risk factors. Br. J. Clin. Pharmacol., 2007, 64, 662-667.
41. van Staa, T.P.; Rietbrock, S.; Setakis, E.; Leufkens, H.G. Does the varied use of NSAIDs explain the differences in the risk of myocardial infarction? J. Intern. Med., 2008, 264, 481-492.
42. Garcia Rodriguez, L.A.; Tacconelli, S.; Patrignani, P. Role of dose potency in the prediction of risk of myocardial infarction associated with nonsteroidal anti-inflammatory drugs in the general population. J. Am. Coll. Cardiol., 2008, 52, 1628-1636.
43. van der Linden, M.W.; van der Bij, S.; Welsing, P.; Kuipers, E.J.; Herings, R.M. The balance between severe cardiovascular and gastrointestinal events among users of selective and non-selective non-steroidal anti-inflammatory drugs. Ann. Rheum. Dis., 2009, 68, 668-673.
44. Fosbol, E.L.; Gislason, G.H.; Jacobsen, S.; Folke, F.; Hansen, M.L.; Schramm, T.K.; Sørensen, R.; Rasmussen, J.N.; Andersen, S.S.; Abildstrom, S.Z.; Traerup, J.; Poulsen, H.E.; Rasmussen, S.; Køber, L. Torp-Pedersen C. Risk of myocardial infarction and death associated with the use of nonsteroidal anti-inflammatory drugs (NSAIDs) among healthy individuals: a nationwide cohort study. Clin. Pharmacol. Ther., 2009, 85, 190-197.
45. Gislason, G.H.; Rasmussen, J.N.; Abildstrom, S.Z.; Rasmussen, J.N.; Abildstrom, S.Z.; Schramm, T.K.; Hansen, M.L.; Fosbøl, E.L.; Sørensen, R.; Folke, F.; Buch, P.; Gadsbøll, N.; Rasmussen, S.; Poulsen, H.E.; Køber, L.; Madsen, M.; Torp-Pedersen, C. Increased mortality and cardiovascular morbidity associated with use of nonsteroidal anti-inflammatory drugs in chronic heart failure. Arch. Intern. Med., 2009, 169, 141-149.
46. Roumie, C.L.; Choma, N.N.; Kaltenbach, L.; Mitchel, Jr, E.F.; Arbogast, P.G.; Griffin, M.R. Non-aspirin NSAIDs, cyclooxygenase-2 inhibitors and risk for cardiovascular events-stroke, acute myocardial infarction, and death from coronary heart disease. Pharmacoepidemiol. Drug Saf., 2009.
47. Cannon, C.P.; Curtis, S.P.; FitzGerald, G.A.; Krum, H.; Kaur, A.; Bolognese, J.A.; Reicin, A.S.; Bombardier, C.; Weinblatt, M.E.; van der Heijde, D.; Erdmann, E.; Laine, L.; MEDAL Steering Committee. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet, 2006, 368, 1771-1781.
48. Baraf, H.S.; Fuentealba, C.; Greenwald, M.; Brzezicki, J.; O'Brien, K.; Soffer, B.; Polis, A.; Bird, S.; Kaur, A.; Curtis, S.P.; EDGE Study Group. Gastrointestinal side effects of etoricoxib in patients with osteoarthritis: results of the Etoricoxib versus Diclofenac Sodium Gastrointestinal Tolerability and Effectiveness (EDGE) trial. J. Rheumatol., 2007, 34, 408-420.
49. Krueger, K.; Lino, L.; Dore, R.; Radominski, S.; Zhang, Y.; Kaur, A.; Simpson, R.; Curtis, S. Gastrointestinal tolerability of etoricoxib in rheumatoid arthritis patients: results of the etoricoxib vs diclofenac sodium gastrointestinal tolerability and effectiveness trial (EDGE-II). Ann. Rheum. Dis., 2008, 67, 315-322.
50. Cannon, C.P.; Curtis, S.P.; Bolognese, J.A.; Laine, L. Clinical trial design and patient demographics of the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) study program: cardiovascular outcomes with etoricoxib versus diclofenac in patients with osteoarthritis and rheumatoid arthritis. Am. Heart J., 2006, 152, 237-245.
51. Combe, B.; Swergold, G.; McLay, J.; McCarthy, T.; Zerbini, C.; Emery, P.; Connors, L.; Kaur, A.; Curtis, S.; Laine, L.; Christopher, P. Cannon8 Cardiovascular safety and gastrointestinal tolerability of etoricoxib vs diclofenac in a randomized controlled clinical trial (The MEDAL study). Rheumatology (Oxford), 2009, 48, 425-432.
52. Derry, P.; Derry, S.; Moore, R.A.; McQuay, H.J. Single dose oral diclofenac for acute postoperative pain in adults. Cochrane. Database Syst. Rev., 2009, (2), CD004768.
53. Buerkle, M.A.; Lehrer, S.; Sohn, H.Y.; Conzen, P.; Pohl, U.; Krotz, F. Selective inhibition of cyclooxygenase-2 enhances platelet adhesion in hamster arterioles in vivo. Circulation, 2004, 110, 2053-2059.
54. Struthmann, L.; Hellwig, N.; Pircher, J.; Sohn, H.Y.; Buerkle, M.A.; Klauss, V.; Mannell, H.; Pohl, U.; Krötz, F. Prothrombotic effects of diclofenac on arteriolar platelet activation and thrombosis in vivo. J. Thromb. Haemost., 2009, 7(10), 1727-1735.
55. Solomon, D.H.; Glynn, R.J.; Levin, R.; Avorn, J. Nonsteroidal anti-inflammatory drug use and acute myocardial infarction. Arch. Intern. Med., 2002, 162, 1099-1104.
56. Kimmel, S.E.; Berlin, J.A.; Reilly, M.; Jaskowiak, J.; Kishel, L.; Chittams, J.; Strom, B.L. The effects of nonselective non-aspirin non-steroidal anti-inflammatory medications on the risk of nonfatal myocardial infarction and their interaction with aspirin. J. Am. Coll. Cardiol., 2004, 43, 985-990.
57. Rahme, E.; Pilote, L.; LeLorier, J. Association between naproxen use and protection against acute myocardial infarction. Arch. Intern. Med., 2002, 162, 1111-1115.
58. Mamdani, M.; Rochon, P.; Juurlink, D.N.; Anderson, G.; Kopp, A.; Naglie, G.; Austin, P.; Laupacis, A. Effect of selective cyclooxygenase 2 inhibitors and naproxen on short-term risk of acute myocardial infarction in the elderly. Arch. Intern. Med., 2003, 163, 481-486.
59. Ray, W.A.; Stein, C.M.; Hall, K.; Daugherty, J.R. Griffin MR. Non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease: an observational cohort study. Lancet, 2002, 359, 118-123.
60. Graham, D.J.; Campen, D.; Hui, R.; Spence, M.; Cheetham, C.; Levy, G.; Shoor, S.; Ray, W.A. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study. Lancet, 2005, 365, 475-481.
61. Knijff-Dutmer, E.A.; Van der Palen, J.; Schut, G.; Van de Laar, M.A. The influence of cyclo-oxygenase specificity of non-steroidal anti-inflammatory drugs on bleeding complications in concomitant coumarine users. QJM, 2003, 96, 513-520.
62. Watson, D.J.; Rhodes, T.; Cai, B.; Guess, H.A. Lower risk of thromboembolic cardiovascular events with naproxen among patients with rheumatoid arthritis. Arch. Intern. Med., 2002, 162, 1105-1110.